TScan Therapeutics, Inc.

TCRXNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$10.3M

▲ 266.7% YoY

Net Income

-$129.8M

▼ 1.8% YoY

EPS

$-1.00

▲ 12.3% YoY

Cash

$152.4M

▼ 14.7% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.